Index / Why Now
Why neuro. Why now.
The conditions for a neurotech boom — validated biology, mature tooling, accelerating regulators, and the most motivated acquirers the field has ever seen — are in place at the same moment. The brain is the last great frontier in human health, and it just became investable.
CNS / Neuro M&A · 2025
$30.7B
Surpassed oncology for the first time in the modern biopharma era.
Acquisition premium
39%
Average premium strategics paid for neuro & CNS targets.
Neuro device market
12% CAGR
$20.2B → $35.7B by 2030 — the fastest-growing segment in medtech.
Patient population
3B+
People living with neurological disorders — the largest untapped population in medicine.
Pharma has already called it.
Pharma's capital rotation is the leading indicator. Facing a roughly $300B patent cliff at the turn of the decade, large pharma is rotating into the brain. In 2025, CNS / neuro M&A reached $30.7B — surpassing oncology ($23.5B) for the first time ever.
Strategics are paying premium valuations for neuro assets, proving what device investors could never prove alone: the underlying neurobiology is now druggable and validated, and payers will reimburse premium neuro therapies. Device acquirers are following the same signal. When both pharma and device strategics converge on the same organ system, the exit environment for venture-backed neurotech is at its most favorable in history.
The base technology has matured.
The wave is investable now because the building blocks finally work. AI-driven signal decoding, sensor miniaturization, and closed-loop stimulation have converted neuro devices from passive hardware into adaptive therapeutic systems that measure a biological signal, interpret it, and act on it — increasingly in a closed loop.
Regulators are accelerating rather than blocking: FDA Breakthrough Device Designation, the START Pilot Program, and new CMS coverage pathways are systematically de-risking novel neuro interventions. Capital has followed, with brain-computer interfaces drawing a growing share of neurotech investment.
The environment for a neurotech boom.
Validated biology, mature base technology, accelerating regulators, and motivated acquirers combine into the boom environment. The markets are enormous and barely penetrated across epilepsy, sleep, neurovascular, and brain-computer interfaces — and the neurology device market is projected to grow from $20.2B in 2025 to $35.7B by 2030, roughly 12% CAGR and the fastest-growing segment in medtech.
And the demand is actuarial, not speculative: more than 3 billion people live with neurological disorders — the largest untapped patient population in medicine — and neurodegenerative disease is projected to become a leading cause of death globally within the next two decades. The need is certain. The tools are ready. The capital is rotating.
Why neuro beats the other verticals.
The moment is set. The edge is the operator.
Markets don't reward being early — they reward being early with the judgment to pick right. Our partners and advisors have built and exited neurotech from the inside: co-founding, funding, and operating neuro and medtech companies, leading Verily's medical-device and neurology teams, and carrying devices from prototype to FDA clearance at Boston Scientific and Apple.
We run an operator-led, partner-only model — no associates, founders work directly with senior operators — co-founded the field's connective tissue in the BrainTech Alliance, and diligence with the combined technical, clinical, and operating depth that separates signal from story. The wave is forming. This is the team built to know which companies ride it.
Figures synthesize public industry research and market commentary (industry sources, 2025–26). They are market estimates for context only — not projections of, or an offer relating to, any fund or its performance.